Dr. James Tomlinson’s research is focused on developing novel engineered antibody fragments as targeting agents against pancreas cancer. He hopes to first translate these antibodies as imaging agents and then secondarily develop these same agents into radioimmunotherapeutics. Additionally, he is involved in collaborations regarding nanoparticle targeting and in vivo click chemistry reactions to enhance targeted therapies.
Selected Cancer-Related Publications:
McCabe KE, Liu B, Marks JD, Tomlinson JS, Wu H, Wu AM. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol. 2012 Jun;14(3):336-47.
Girgis MD, Kenanova V, Olafsen T, McCabe KE, Wu AM, Tomlinson JS. Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. J Surg Res. 2011 Oct;170(2):169-78. Epub 2011 Apr 20
Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer. Int J Mol Imaging. 2011 Sep 6;2011:834515.
Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment. EJNMMI Res. 2011 Nov 7;1(1):24.
Wasif N, Ko CY, Farrell J, Wainberg Z, Hines OJ, Reber H, Tomlinson JS. Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol. 2010 Sep;17(9):2312-20. Epub 2010 Apr 27